Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis

  • After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
  • Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1  
/by

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis

  • After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1
  • Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease1  
/by

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis

  • If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe
  • Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2
/by

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis

  • If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe
  • Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2
/by

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis

  • If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe
  • Scemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments1,2
/by

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
arcticnovartis

  • In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1

  • eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 
/by

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 
arcticnovartis

  • Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025
/by

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis announces commencement of tender offer to acquire Tourmaline Bio
arcticnovartis

Basel, September 29, 2025 – Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding.

/by